SCHEMBL28618673

SCHEMBL28618673

COC(=O)c1c(NC(=O)C2CC2)sc2c1C[C@@H](N)CC2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.70
HSD17B10 Q99714 3/20 0.70
MAPT P10636 3/20 0.70
ALDH1A1 P00352 9/20 0.57
GAA P10253 1/20 0.57
FLT3 P36888 1/20 0.52
RAB9A P51151 2/20 0.50
CNR2 P34972 3/20 0.48
CNR1 P21554 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 2/20 0.46
CHD1L Q86WJ1 1/20 0.46
PARP9 Q8IXQ6 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46
MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21603914 1.00 KDM4E (0.70) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL21597779 0.89 KMT2A (0.59) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL21603968 0.86 KDM4E (0.71) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL21597701 0.85 MAPT (0.51) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL21603922 0.82 KDM4E (1.00) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL21597822 0.81 CNR2 (0.57) KDM4EHSD17B10MAPTFLT3CNR2
SCHEMBL21597745 0.80 CNR2 (0.51) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL28607611 0.80 KDM4E (0.53) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL28607607 0.80 KDM4E (0.53) KDM4EHSD17B10MAPTALDH1A1GAA
SCHEMBL21597817 0.79 CNR2 (0.50) KDM4EHSD17B10MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 KDM4E 3965/4885HSD17B10 1200/4885MAPT 2356/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 KDM4E 3965/4885HSD17B10 1200/4885MAPT 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.